SCHEMBL6512640

SCHEMBL6512640

COc1ccc(C(N)=O)cc1C(N)=O

nearest known ligand 0.60

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPK1 P28482 1/20 0.60
CYP1A2 P05177 2/20 0.55
CYP3A4 P08684 1/20 0.55
CYP2C9 P11712 1/20 0.55
TSHR P16473 1/20 0.55
CYP2C19 P33261 1/20 0.55
CA1 P00915 2/20 0.53
CA2 P00918 2/20 0.53
CA12 O43570 1/20 0.53
CA4 P22748 1/20 0.53
CA6 P23280 1/20 0.53
CA7 P43166 1/20 0.53
TPMT P51580 1/20 0.53
CA9 Q16790 1/20 0.53
CA14 Q9ULX7 1/20 0.53
PARP1 P09874 2/20 0.52
PARP10 Q53GL7 2/20 0.52
PARP2 Q9UGN5 1/20 0.52
PARP4 Q9UKK3 1/20 0.52
HTT P42858 2/20 0.51

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1353136 0.89 CA12 (0.70) MAPK1CYP1A2CYP3A4CYP2C9TSHR
SCHEMBL1353135 0.89 CA1 (0.59) MAPK1CYP1A2CYP3A4CYP2C9TSHR
SCHEMBL11449611 0.89 HDAC1 (0.54) MAPK1CYP1A2CYP3A4CYP2C9TSHR
SCHEMBL20944605 0.87 MAPK1 (0.55) MAPK1CYP1A2CYP3A4CYP2C9TSHR
SCHEMBL29415167 0.86 MAPK1 (0.77) MAPK1CYP1A2CYP3A4CYP2C9TSHR
SCHEMBL335681 0.86 MAPK1 (0.77) MAPK1CYP1A2CYP3A4CYP2C9TSHR
SCHEMBL3787323 0.85 MAPK1 (0.60) MAPK1CYP1A2CYP3A4CYP2C9TSHR
Hydrochloric Acid SCHEMBL5154533 0.84 MAPK1 (0.74) MAPK1CYP1A2CYP3A4CYP2C9TSHR
SCHEMBL11466941 0.83 GSK3B (0.51) MAPK1CYP1A2CYP3A4CYP2C9TSHR
SCHEMBL2190365 0.82 ACHE (0.59) MAPK1CYP1A2CYP3A4CYP2C9TSHR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250268903-A1 RXFP1 AGONISTS BRISTOL MYERS SQUIBB CO (US) 2025-08-28 US disclosed
CN-101172959-B N,N*-2[fluoroform (oxygen) group] substituted phenyl derivant of 4-methoxy-1,3-benzene diamide and uses of the same UNIV TIANJIN TECHNOLOGY 2010-12-15 CN disclosed
CN-101172958-A N,N*-2(2substituted phenyl) derivant of - 4-methoxy-1,3-benzol diamide and use of the same UNIV TIANJIN TECHNOLOGY (CN) 2008-05-07 CN disclosed
CN-101172959-A N,N*-2[fluoroform (oxygen) group] substituted phenyl derivant of 4-methoxy-1,3-benzene diamide and uses of the same UNIV TIANJIN TECHNOLOGY (CN) 2008-05-07 CN disclosed
US-20050004126-A1 Method of determining potential allosterically-binding matrix metalloproteinase inhibitors ANDRIANJARA CHARLES (FR) 2005-01-06 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050004126-A1 Method of determining potential allosterically-binding matrix metalloproteinase inhibitors MMP13, MMP12, MMP25 MAPK1 861/4885CYP1A2 3013/4885CYP3A4 1725/4885
US-20250268903-A1 RXFP1 AGONISTS RXFP1, RXFP2, RXFP3 MAPK1 771/4885CYP1A2 1125/4885CYP3A4 3135/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.